TIME named Moderna one of the world's most impactful companies for 2026.
The ranking, conducted with Statista, evaluates net-positive contributions to health, society, knowledge, and the environment.
CEO Stéphane Bancel credited the recognition to the company's mRNA science.
In 2026, Moderna received European approval for its fourth product. The combination flu and COVID vaccine is mCOMBRIAX®.